07:00 , Mar 28, 2016 |  BC Week In Review  |  Company News

Bioject, Inovio deal

Inovio will acquire Bioject’s assets for $1 million in cash and $4.5 million in Inovio stock. Inovio will combine Bioject’s injection technology with Inovio’s skin-surface electroporation technology to “facilitate preventative immunization.” The deal is subject...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Bioject drug delivery news

Bioject retained financial advisor Snehal Patel to explore strategic alternatives, including the sale of the company. In its 3Q11 earnings, the company disclosed that in November it reduced headcount by 12 (38%) to 20 and...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Company News

Bioject management update

Bioject Medical Technologies Inc. (OTCBB:BJCT), Tualatin, Ore.   Business: Drug delivery   Departed: Ralph Makar as president and CEO; he is succeeded by Mark Logomasini, a director, as interim president and CEO  ...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Pennvax-G: Interim Phase I data

Interim data from 11 healthy volunteers in a U.S. cohort of the open-label Phase I RV262 trial showed that Inovio's Pennvax-G vaccine boosted with the modified vaccinia Ankara-Chiang Mai Double Recombinant (MVA-CMDR) virus vector vaccine...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Company News

Bioject, PATH, WHO deal

Bioject will supply PATH and WHO with its Intradermal (ID) Pen disposable-syringe jet injector for use in vaccine delivery in developing countries. WHO and PATH will provide Bioject with funding to produce the pens. Further...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Pennvax-G: Phase Ib started

NIH and the U.S. Department of Defense's Military HIV Research Program (MHRP) began the international Phase Ib RV262 trial in 92 healthy volunteers to evaluate Inovio's Pennvax-G vaccine boosted with the modified vaccinia Ankara-Chiang Mai...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Biojector 2000: Phase I/II data

Data from a double-blind, Dominican Republican Phase I/II trial in 450 infants ages 6-24 months showed that 0.1 mL Vaxigrip influenza vaccine delivered intradermally via the Biojector 2000 needle-free injection system produced a seroconversion rate...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Clinical News

HIV vaccine: Phase I start

In May, Cyto Pulse will begin a double-blind, placebo-controlled Swedish Phase I trial in 48 healthy volunteers. The HIV DNA vaccine is delivered via Zetajet needle-free injection technology from Bioject Medical Technologies Inc. (OTCBB:BJCT, Tualatin,...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Company News

Bioject board of directors update

Bioject Medical Technologies Inc. (OTCBB:BJCT), Tualatin, Ore.   Business: Drug Delivery   Appointed: Al Hansen, principal at Signet Healthcare Partners; and Mark Logomasini, director of business development for the government sector group of Sigma-Aldrich Corp....
07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

Zetajet regulatory update

Bioject received 510(k) clearance from FDA for its Zetajet Needle-Free Injection Therapy System, which is designed to deliver vaccines and injectable therapeutics subcutaneously or intramuscularly. The company will seek partners interested in using the Zetajet...